RACHEL SCHIFF

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
AddressOne Baylor Plaza
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentBreast Center
    DivisionBreast Cancer Center

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Molecular & Cellular Biology
    DivisionMolecular & Cellular Biology


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mouabbi JA, Osborne CK, Schiff R, Rimawi MF. Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Breast Cancer Res Treat. 2021 Sep 13. PMID: 34515904.
      Citations:    Fields:    
    2. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4939. PMID: 34470810.
      Citations:    Fields:    
    3. Jeselsohn R, Schiff R, Grinshpun A. Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2. Cancer Cell. 2021 Aug 21. PMID: 34506738.
      Citations:    Fields:    
    4. Abdulkareem NM, Bhat R, Qin L, Vasaikar S, Gopinathan A, Mitchell T, Shea MJ, Nanda S, Thangavel H, Zhang B, De Angelis C, Schiff R, Trivedi MV. A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer. FASEB J. 2021 07; 35(7):e21719. PMID: 34110646.
      Citations:    Fields:    Translation:HumansAnimalsCells
    5. Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R. Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021 May 27; 7(1):63. PMID: 34045483.
      Citations:    
    6. Bado IL, Zhang W, Hu J, Xu Z, Wang H, Sarkar P, Li L, Wan YW, Liu J, Wu W, Lo HC, Kim IS, Singh S, Janghorban M, Muscarella AM, Goldstein A, Singh P, Jeong HH, Liu C, Schiff R, Huang S, Ellis MJ, Gaber MW, Gugala Z, Liu Z, Zhang XH. The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. Dev Cell. 2021 04 19; 56(8):1100-1117.e9. PMID: 33878299.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    7. Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, Rognoni C, Di Leo A, Locci M, Jerusalem G, Del Mastro L, Puglisi F, Conte P, De Laurentiis M, Pusztai L, Rimawi MF, Schiff R, Arpino G, De Placido S, Prat A, Generali D. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers (Basel). 2021 Mar 22; 13(6). PMID: 33810205.
      Citations:    
    8. Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 May 01; 27(9):2648-2662. PMID: 33542078.
      Citations:    Fields:    
    9. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4870-4882. PMID: 33536276.
      Citations: 2     Fields:    
    10. Yang Y, Choppavarapu L, Fang K, Naeini AS, Nosirov B, Li J, Yang K, He Z, Zhou Y, Schiff R, Li R, Hu Y, Wang J, Jin VX. The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. Biochim Biophys Acta Gene Regul Mech. 2020 11; 1863(11):194631. PMID: 32956836.
      Citations:    Fields:    Translation:HumansCells
    11. Li L, Lin L, Veeraraghavan J, Hu Y, Wang X, Lee S, Tan Y, Schiff R, Wang XS. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Res. 2020 08 08; 22(1):84. PMID: 32771039.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    12. Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, Feit AS, Bergholz J, Michowski W, Otto T, Sheng Q, Loo A, Michael W, Tiedt R, DeAngelis C, Schiff R, Jiang B, Jovanovic B, Nowak K, Ericsson M, Cameron M, Gray N, Dillon D, Zhao JJ, Sabatini DM, Jeselsohn R, Brown M, Polyak K, Sicinski P. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv. 2020 Jun; 6(25):eabb2210. PMID: 32704543.
      Citations: 8     Fields:    
    13. Bi M, Zhang Z, Jiang YZ, Xue P, Wang H, Lai Z, Fu X, De Angelis C, Gong Y, Gao Z, Ruan J, Jin VX, Marangoni E, Montaudon E, Glass CK, Li W, Huang TH, Shao ZM, Schiff R, Chen L, Liu Z. Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. Nat Cell Biol. 2020 06; 22(6):701-715. PMID: 32424275.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    14. Wu F, Hua Y, Kaochar S, Nie S, Lin YL, Yao Y, Wu J, Wu X, Fu X, Schiff R, Davis CM, Robertson M, Ehli EA, Coarfa C, Mitsiades N, Song Y. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP. J Med Chem. 2020 05 14; 63(9):4716-4731. PMID: 32314924.
      Citations: 5     Fields:    Translation:HumansCells
    15. Zhou Y, Gerrard DL, Wang J, Li T, Yang Y, Fritz AJ, Rajendran M, Fu X, Stein G, Schiff R, Lin S, Frietze S, Jin VX. Author Correction: Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance. Nat Commun. 2020 04 20; 11(1):1967. PMID: 32313124.
      Citations:    Fields:    
    16. Stossi F, Dandekar RD, Mancini MG, Gu G, Fuqua SAW, Nardone A, De Angelis C, Fu X, Schiff R, Bedford MT, Xu W, Johansson HE, Stephan CC, Mancini MA. Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity. Nucleic Acids Res. 2020 02 28; 48(4):1800-1810. PMID: 31930333.
      Citations: 3     Fields:    Translation:HumansCells
    17. Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, Mutch D, Watson MA, Ma C, Ademuyiwa FO, Rimawi MF, Schiff R, Hoog J, Jacobs S, Malovannaya A, Hyslop T, Clauser KR, Mani DR, Perou CM, Miles G, Zhang B, Gillette MA, Carr SA, Ellis MJ. Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27; 11(1):532. PMID: 31988290.
      Citations: 9     Fields:    Translation:HumansCells
    18. Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, Martínez O, Adamo B, Vidal M, Muñoz M, Fernández-Martinez A, Rognoni C, Griguolo G, Guarneri V, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrasa P, De Placido S, Schiff R, Veeraraghavan J, Rimawi MF, Osborne CK, Pernas S, Perou CM, Carey LA, Prat A. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2020 Mar; 84:101965. PMID: 32000054.
      Citations: 11     Fields:    Translation:Humans
    19. Osborne CK, Schiff R, Rimawi M. DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER. Trans Am Clin Climatol Assoc. 2020; 131:119-126. PMID: 32675852.
      Citations:    Fields:    
    20. Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54. PMID: 31037288.
      Citations: 22     Fields:    Translation:Humans
    21. Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020 04; 17(4):233-250. PMID: 31836877.
      Citations: 23     Fields:    Translation:Humans
    22. Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, Reis-Filho JS, Cohen O, Wagle N, Nardone A, Jeselsohn R, Brown M, Rimawi MF, Osborne CK, Schiff R. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci U S A. 2019 Dec 11. PMID: 31826955.
      Citations: 15     Fields:    
    23. Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827. PMID: 31662331.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    24. De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745. PMID: 31653641.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    25. Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, Creighton CJ, Chen F, Dobrolecki LE, George JT, Kumar T, Abdulkareem NM, Mao S, Nardone A, Rimawi M, Osborne CK, Lewis MT, Levine H, Zhang B, Schiff R, Giuliano M, Trivedi MV. A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. J Clin Med. 2019 10 24; 8(11). PMID: 31652963.
      Citations: 10     
    26. Biswal NC, Fu X, Jagtap JM, Shea MJ, Kumar V, Lords T, Roy R, Schiff R, Joshi A. In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer. J Biophotonics. 2020 01; 13(1):e201900180. PMID: 31595691.
      Citations:    Fields:    Translation:HumansAnimalsCells
    27. Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X, Sun Y. The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20528-20538. PMID: 31548378.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    28. Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330. PMID: 31420371.
      Citations: 11     Fields:    Translation:HumansCells
    29. Zhou Y, Gerrard DL, Wang J, Li T, Yang Y, Fritz AJ, Rajendran M, Fu X, Stein G, Schiff R, Lin S, Frietze S, Jin VX. Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance. Nat Commun. 2019 04 03; 10(1):1522. PMID: 30944316.
      Citations: 9     Fields:    Translation:HumansCells
    30. Ramirez AB, Bhat R, Sahay D, De Angelis C, Thangavel H, Hedayatpour S, Dobrolecki LE, Nardone A, Giuliano M, Nagi C, Rimawi M, Osborne CK, Lewis MT, Stilwell JL, Kaldjian EP, Schiff R, Trivedi MV. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12; 19(1):220. PMID: 30871481.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    31. Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339. PMID: 30555156.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    32. Guarducci C, Bonechi M, Benelli M, Biagioni C, Boccalini G, Romagnoli D, Verardo R, Schiff R, Osborne CK, De Angelis C, Di Leo A, Malorni L, Migliaccio I. Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer. 2018; 4:38. PMID: 30511015.
      Citations: 15     
    33. Schiff R, Jeselsohn R. Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine. Cancer Discov. 2018 11; 8(11):1352-1354. PMID: 30385523.
      Citations: 1     Fields:    Translation:Humans
    34. Campbell PS, Mavingire N, Khan S, Rowland LK, Wooten JV, Opoku-Agyeman A, Guevara A, Soto U, Cavalli F, Loaiza-Pérez AI, Nagaraj G, Denham LJ, Adeoye O, Jenkins BD, Davis MB, Schiff R, Brantley EJ. AhR ligand aminoflavone suppresses a6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells. J Cell Physiol. 2018 01; 234(1):108-121. PMID: 30076704.
      Citations: 6     Fields:    Translation:HumansCells
    35. Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES. Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. Mol Cancer Ther. 2018 05; 17(5):921-930. PMID: 29592880.
      Citations: 3     Translation:HumansAnimalsCells
    36. Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511. PMID: 29578538.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    37. Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, Al-Rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar VA, Osborne CK, Schiff R, Trivedi MV. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292. PMID: 29574636.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    38. Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV. Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancer Res. 2018 02 15; 78(4):845-852. PMID: 29437766.
      Citations: 52     Fields:    Translation:HumansCells
    39. Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERa-GREB1 Transcriptional Axis. Cancer Res. 2018 02 01; 78(3):671-684. PMID: 29212856.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    40. Ito K, Park SH, Katsyv I, Zhang W, De Angelis C, Schiff R, Irie HY. PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells. NPJ Breast Cancer. 2017; 3:45. PMID: 29167821.
      Citations: 9     
    41. Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740. PMID: 29110152.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    42. Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, Osborne CK, Schiff R. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast. 2017 Aug; 34 Suppl 1:S19-S26. PMID: 28687441.
      Citations: 18     Fields:    Translation:HumansCells
    43. Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M. Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc Natl Acad Sci U S A. 2017 05 30; 114(22):E4482-E4491. PMID: 28507152.
      Citations: 26     Fields:    Translation:HumansCells
    44. Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134. PMID: 28487443.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    45. Jeselsohn R, De Angelis C, Brown M, Schiff R. The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. Curr Oncol Rep. 2017 May; 19(5):35. PMID: 28374222.
      Citations: 34     Fields:    Translation:HumansCells
    46. Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, Schiff R, Wang XS, Li K. Identification of MYST3 as a novel epigenetic activator of ERa frequently amplified in breast cancer. Oncogene. 2017 05 18; 36(20):2910-2918. PMID: 27893709.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    47. Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609. PMID: 27791031.
      Citations: 46     Fields:    Translation:HumansCells
    48. Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R, Wang XS. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nat Commun. 2016 10 03; 7:12991. PMID: 27694828.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    49. Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506. PMID: 27671678.
      Citations: 31     Fields:    Translation:HumansCells
    50. Kim JA, Anurag M, Veeraraghavan J, Schiff R, Li K, Wang XS. Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint. Mol Cancer Res. 2016 10; 14(10):920-927. PMID: 27489360.
      Citations: 10     Fields:    Translation:HumansCells
    51. Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81. PMID: 26965145.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    52. Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. The changing role of ER in endocrine resistance. Breast. 2015 Nov; 24 Suppl 2:S60-6. PMID: 26271713.
      Citations: 24     Fields:    Translation:HumansCells
    53. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015 Oct; 12(10):573-83. PMID: 26122181.
      Citations: 152     Fields:    Translation:Humans
    54. Chung A, Choi M, Han BC, Bose S, Zhang X, Medina-Kauwe L, Sims J, Murali R, Taguiam M, Varda M, Schiff R, Giuliano A, Cui X. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clin Breast Cancer. 2015 Dec; 15(6):448-457.e2. PMID: 26248960.
      Citations: 5     Fields:    Translation:Humans
    55. Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003. PMID: 26015514.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    56. Suo J, Medina D, Herrera S, Zheng ZY, Jin L, Chamness GC, Contreras A, Gutierrez C, Hilsenbeck S, Umar A, Foekens JA, Hanash S, Schiff R, Zhang XH, Chang EC. Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells. Cell Biosci. 2015; 5:10. PMID: 25774287.
      Citations: 5     
    57. Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3. PMID: 25572662.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    58. Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28. PMID: 25587647.
      Citations: 89     Fields:    Translation:Humans
    59. Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 2015; 14(4):648-55. PMID: 25590338.
      Citations: 34     Translation:AnimalsCells
    60. Rimawi MF, De Angelis C, Schiff R. Resistance to Anti-HER2 Therapies in Breast Cancer. Am Soc Clin Oncol Educ Book. 2015; e157-64. PMID: 25993167.
      Citations: 9     Fields:    Translation:HumansAnimals
    61. Sine J, Urban C, Thayer D, Charron H, Valim N, Tata DB, Schiff R, Blumenthal R, Joshi A, Puri A. Photo activation of HPPH encapsulated in "Pocket" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts. Int J Nanomedicine. 2015; 10:125-45. PMID: 25565809.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    62. Karlin KL, Mondal G, Hartman JK, Tyagi S, Kurley SJ, Bland CS, Hsu TY, Renwick A, Fang JE, Migliaccio I, Callaway C, Nair A, Dominguez-Vidana R, Nguyen DX, Osborne CK, Schiff R, Yu-Lee LY, Jung SY, Edwards DP, Hilsenbeck SG, Rosen JM, Zhang XH, Shaw CA, Couch FJ, Westbrook TF. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32. PMID: 25453754.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    63. Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430. PMID: 25212826.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    64. Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577. PMID: 25099679.
      Citations: 59     Fields:    Translation:HumansAnimalsCells
    65. Ayala-Orozco C, Urban C, Bishnoi S, Urban A, Charron H, Mitchell T, Shea M, Nanda S, Schiff R, Halas N, Joshi A. Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors. J Control Release. 2014 Oct 10; 191:90-97. PMID: 25051221.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    66. Ayala-Orozco C, Urban C, Knight MW, Urban AS, Neumann O, Bishnoi SW, Mukherjee S, Goodman AM, Charron H, Mitchell T, Shea M, Roy R, Nanda S, Schiff R, Halas NJ, Joshi A. Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells. ACS Nano. 2014 Jun 24; 8(6):6372-81. PMID: 24889266.
      Citations: 44     Fields:    Translation:HumansAnimals
    67. Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19. PMID: 24874954.
      Citations: 81     Fields:    Translation:HumansAnimalsCells
    68. Putluri N, Maity S, Kommagani R, Kommangani R, Creighton CJ, Putluri V, Chen F, Nanda S, Bhowmik SK, Terunuma A, Dorsey T, Nardone A, Fu X, Shaw C, Sarkar TR, Schiff R, Lydon JP, O'Malley BW, Ambs S, Das GM, Michailidis G, Sreekumar A. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402. PMID: 25016594.
      Citations: 26     Fields:    Translation:HumansCells
    69. Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 2014 Mar 26; 6(229):229ra41. PMID: 24670685.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    70. Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, Klinowska T, Osborne CK, Rimawi MF, Schiff R. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat. 2014 Apr; 144(2):263-72. PMID: 24554387.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    71. Fan Y, Ge N, Wang X, Sun W, Mao R, Bu W, Creighton CJ, Zheng P, Vasudevan S, An L, Yang J, Zhao YJ, Zhang H, Li XN, Rao PH, Leung E, Lu YJ, Gray JW, Schiff R, Hilsenbeck SG, Osborne CK, Yang J, Zhang H. Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86. PMID: 24122835.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    72. Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambs S. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014 Jan; 124(1):398-412. PMID: 24316975.
      Citations: 181     Fields:    Translation:HumansCells
    73. Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6389-97. PMID: 24298069.
      Citations: 84     Fields:    Translation:Humans
    74. Zhang Y, Tseng CC, Tsai YL, Fu X, Schiff R, Lee AS. Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One. 2013; 8(11):e80071. PMID: 24244613.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    75. Fu X, Osborne CK, Schiff R. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast. 2013 Aug; 22 Suppl 2:S12-8. PMID: 24011769.
      Citations: 34     Fields:    Translation:HumansCells
    76. Giuliano M, Trivedi MV, Schiff R. Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. Breast Care (Basel). 2013 Aug; 8(4):256-62. PMID: 24415978.
      Citations: 29     
    77. Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Chi D, Fu X, Schiff R, Brown M, Brugge JS. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell. 2013 Jun 10; 23(6):753-67. PMID: 23764000.
      Citations: 33     Fields:    Translation:HumansCells
    78. Parma J, Pavlick A, Schiff R, Osborne CK, Chang JC, Rimawi M, Trivedi MV. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy. 2013 Oct; 33(10):1126-9. PMID: 23744830.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    79. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97. PMID: 23737486.
      Citations: 184     Fields:    Translation:HumansAnimalsCells
    80. Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31. PMID: 23569315.
      Citations: 86     Fields:    Translation:HumansCellsCTClinical Trials
    81. Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93. PMID: 22644656.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    82. Giuliano M, Trivedi MV, Schiff R. Die and let live: harnessing BikDD to combat breast cancer stem cells. Breast Cancer Res. 2012 May 23; 14(3):310. PMID: 22621279.
      Citations:    Fields:    Translation:HumansAnimalsCells
    83. Xu J, Wan M, He Q, Bassett RL, Fu X, Chen AC, Shi F, Creighton CJ, Schiff R, Huo L, Liu D. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):531-41. PMID: 22576469.
      Citations: 13     Fields:    Translation:HumansCells
    84. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53. PMID: 22157079.
      Citations: 194     Fields:    Translation:HumansAnimalsCells
    85. Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res. 2012 Jan 01; 18(1):118-26. PMID: 21980134.
      Citations: 22     Fields:    Translation:HumansCells
    86. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. ß1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31; 13(4):R84. PMID: 21884573.
      Citations: 78     Fields:    Translation:HumansCells
    87. Fu X, Huang C, Schiff R. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response. Breast Cancer Res. 2011 Apr 20; 13(2):307. PMID: 21575280.
      Citations: 6     Fields:    Translation:HumansCells
    88. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18. PMID: 21376233.
      Citations: 118     Fields:    Translation:HumansCells
    89. Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, Herschkowitz JI, Burrows AE, Ciccia A, Sun T, Schmitt EM, Bernardi RJ, Fu X, Bland CS, Cooper TA, Schiff R, Rosen JM, Westbrook TF, Elledge SJ. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70. PMID: 21307310.
      Citations: 300     Fields:    Translation:HumansAnimalsCells
    90. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59. PMID: 21220480.
      Citations: 70     Fields:    Translation:HumansCellsCTClinical Trials
    91. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011 Jan; 135(1):55-62. PMID: 21204711.
      Citations: 133     Fields:    Translation:Humans
    92. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233-47. PMID: 20887199.
      Citations: 427     Fields:    Translation:HumansCells
    93. Cheng CM, Li H, Gasman S, Huang J, Schiff R, Chang EC. Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies. Mol Cell Biol. 2011 Mar; 31(5):983-97. PMID: 21189290.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    94. Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61. PMID: 21138857.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    95. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73. PMID: 21135276.
      Citations: 109     Fields:    Translation:HumansCells
    96. Bardhan R, Chen W, Bartels M, Perez-Torres C, Botero MF, McAninch RW, Contreras A, Schiff R, Pautler RG, Halas NJ, Joshi A. Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo. Nano Lett. 2010 Dec 08; 10(12):4920-8. PMID: 21090693.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    97. Suo J, Snider SJ, Mills GB, Creighton CJ, Chen AC, Schiff R, Lloyd RE, Chang EC. Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium. Oncogene. 2011 Feb 10; 30(6):724-36. PMID: 20890303.
      Citations: 14     Fields:    Translation:HumansCells
    98. Toneff MJ, Du Z, Dong J, Huang J, Sinai P, Forman J, Hilsenbeck S, Schiff R, Huang S, Li Y. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia. 2010 Sep; 12(9):718-26. PMID: 20824048.
      Citations: 18     Fields:    Translation:AnimalsCells
    99. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40. PMID: 20569503.
      Citations: 104     Fields:    Translation:HumansCells
    100. Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, Natarajan V, Pyne NJ, Pyne S. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol. 2010 Aug; 30(15):3827-41. PMID: 20516217.
      Citations: 49     Fields:    Translation:HumansCells
    101. Carpin LB, Bickford LR, Agollah G, Yu TK, Schiff R, Li Y, Drezek RA. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat. 2011 Jan; 125(1):27-34. PMID: 20217215.
      Citations: 34     Fields:    Translation:HumansCells
    102. Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010 Mar 01; 116(5):1234-42. PMID: 20082448.
      Citations: 80     Fields:    Translation:Humans
    103. Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res. 2009 Jul 15; 15(14):4712-21. PMID: 19584166.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    104. Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res. 2008; 10(6):R105. PMID: 19087274.
      Citations: 55     Fields:    Translation:Humans
    105. Kang YK, Schiff R, Ko L, Wang T, Tsai SY, Tsai MJ, O'Malley BW. Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis. Cancer Res. 2008 Oct 01; 68(19):7887-96. PMID: 18829545.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    106. Sengupta S, Schiff R, Katzenellenbogen BS. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat. 2009 Sep; 117(2):243-51. PMID: 18807177.
      Citations: 15     Fields:    Translation:HumansCells
    107. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501. PMID: 18794137.
      Citations: 72     Fields:    Translation:HumansAnimalsCells
    108. Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99. PMID: 18425577.
      Citations: 35     Fields:    Translation:HumansCells
    109. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33. PMID: 18245484.
      Citations: 198     Fields:    Translation:HumansAnimalsCells
    110. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008 Apr; 29(2):217-33. PMID: 18216219.
      Citations: 192     Fields:    Translation:Humans
    111. Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res. 2007 Dec 01; 13(23):6921-5. PMID: 18056165.
      Citations: 20     Fields:    Translation:Humans
    112. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, Sevick-Muraca EM. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007 Sep; 48(9):1501-10. PMID: 17785729.
      Citations: 87     Fields:    Translation:HumansAnimalsCells
    113. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007 May 02; 99(9):694-705. PMID: 17470737.
      Citations: 81     Fields:    Translation:HumansAnimalsCells
    114. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007 Apr 01; 13(7):1950-4. PMID: 17404074.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    115. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006 Dec; 13 Suppl 1:S15-24. PMID: 17259554.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    116. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73. PMID: 16912207.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    117. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27. PMID: 16541323.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    118. Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators? Nat Clin Pract Oncol. 2006 Mar; 3(3):134-5. PMID: 16520802.
      Citations:    Fields:    
    119. Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol. 2006 Mar; 20(3):491-502. PMID: 16306086.
      Citations: 112     Fields:    Translation:HumansCells
    120. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20. PMID: 16273359.
      Citations: 65     Fields:    Translation:HumansCells
    121. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct 20; 23(30):7721-35. PMID: 16234531.
      Citations: 160     Fields:    Translation:HumansCells
    122. Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65. PMID: 16236516.
      Citations: 35     Fields:    Translation:Humans
    123. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61. PMID: 16145046.
      Citations: 135     Fields:    Translation:HumansCells
    124. Schiff R, Osborne CK. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 2005; 7(5):205-11. PMID: 16168139.
      Citations: 26     Fields:    Translation:Humans
    125. Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, Li Y. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene. 2005 Jun 16; 24(26):4220-31. PMID: 15824740.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    126. Osborne CK, Schiff R. Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol. 2005 May; 95(1-5):183-7. PMID: 16019204.
      Citations: 6     Fields:    Translation:Humans
    127. Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K, Reddy KB. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene. 2005 Apr 28; 24(19):3166-76. PMID: 15735693.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    128. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005 Mar 10; 23(8):1616-22. PMID: 15755967.
      Citations: 98     Fields:    Translation:HumansCells
    129. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76. PMID: 15753463.
      Citations: 163     Fields:    Translation:HumansAnimalsCells
    130. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8. PMID: 15710948.
      Citations: 88     Fields:    Translation:HumansCTClinical Trials
    131. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):865s-70s. PMID: 15701879.
      Citations: 122     Fields:    Translation:HumansCells
    132. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35. PMID: 15199112.
      Citations: 367     Fields:    Translation:HumansAnimalsCells
    133. Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):327S-330S. PMID: 14734487.
      Citations: 1     Fields:    Translation:HumansCells
    134. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):331S-6S. PMID: 14734488.
      Citations: 124     Fields:    Translation:HumansAnimalsCells
    135. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003 Dec; 12(6):362-7. PMID: 14659106.
      Citations: 34     Fields:    Translation:HumansCells
    136. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J, Lee AV. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res. 2003 Sep 01; 63(17):5203-8. PMID: 14500345.
      Citations: 38     Fields:    Translation:HumansCells
    137. Schiff R, Chamness GC, Brown PH. Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 2003; 5(5):228-31. PMID: 12927029.
      Citations: 8     Fields:    Translation:HumansAnimals
    138. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003 May 15; 63(10):2434-9. PMID: 12750263.
      Citations: 39     Fields:    Translation:Humans
    139. Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003 Aug; 17(8):1543-54. PMID: 12730327.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    140. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61. PMID: 12618500.
      Citations: 241     Fields:    Translation:HumansCells
    141. Lee AV, Schiff R, Cui X, Sachdev D, Yee D, Gilmore AP, Streuli CH, Oesterreich S, Hadsell DL. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):516S-23S. PMID: 12538509.
      Citations: 2     Fields:    Translation:HumansCells
    142. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):447S-54S. PMID: 12538499.
      Citations: 96     Fields:    Translation:HumansCells
    143. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9. PMID: 12400010.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    144. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PMID: 11916222.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    145. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34. PMID: 11106684.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    146. Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, Moore JT. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 1999 Nov 01; 59(21):5425-8. PMID: 10554010.
      Citations: 35     Fields:    Translation:HumansCells
    SCHIFF's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (480)
    Explore
    _
    Co-Authors (73)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _